QIAGEN Forms Lung Cancer Expert Alliance

Key opinion leaders' expertise to guide design of new gene panels for GeneReader NGS

Jun 02, 2016, 16:05 ET from QIAGEN N.V.

HILDEN, Germany and GERMANTOWN, Maryland, June 2, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations.

The members of the consortium will work with a QIAGEN team to guide selection of the genes and variants for the panels, development of the NGS workflows, and the verification of both the panels and workflows. The results of these validation studies will be published by the Expert Alliance. From the work of the consortium, QIAGEN will deliver a series of Sample to Insight lung cancer NGS panel workflows for use with both tissue and liquid biopsy samples on QIAGEN's GeneReader NGS System, the world's first truly complete NGS workflow - from Sample to Insight.

Click here for full press release

Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email: pr@qiagen.com http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN   pr.qiagen.com

Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: ir@qiagen.com ir.qiagen.com